Eventide Asset Management ALKS Position
Exited9-Fund ConvergenceEventide Asset Management exited their position in Alkermes plc (ALKS) in Q3 2023, after holding the stock for 2 quarters.
The position was first reported in Q2 2023 and has been tracked across 2 quarterly 13F filings.
ALKS is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ALKS 2680 in 77 days (Jun 30, 2026), making the timing of Eventide's position particularly relevant.
Short interest stands at 17.9% of float with 10.0 days to cover, indicating significant bearish positioning against the stock.
About Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Full company profile →Short Interest
17.9%
10.0 days to cover
Eventide Asset Management ALKS Position History
Frequently Asked Questions
Does Eventide Asset Management own ALKS?
No. Eventide Asset Management exited their position in Alkermes plc (ALKS) in Q3 2023. They previously held the stock for 2 quarters.
How many hedge funds own ALKS?
9 specialist biotech hedge funds currently hold ALKS, including Baker Bros. Advisors, RTW Investments, Deep Track Capital and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy ALKS?
Eventide Asset Management's position in ALKS was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's ALKS position increasing or decreasing?
Eventide Asset Management completely exited their ALKS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ALKSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →